Literature DB >> 12102655

Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.

Sanna Taskinen1, Petri T Kovanen, Hanna Jarva, Seppo Meri, Markku O Pentikäinen.   

Abstract

C-reactive protein (CRP), an acute-phase reactant, is present in atherosclerotic human arterial intima in association with lipids. In the present work we studied interactions between CRP and LDL on microtitre wells, where either CRP or LDL was immobilized. LDL was modified by vortex-mixing, oxidation, or by lipolysis with phospholipase A(2) or with sphingomyelinase or a combination of trypsin and cholesterol esterase. We found that CRP bound only to LDL modified by trypsin/cholesterol esterase or by sphingomyelinase and that this binding was Ca(2+)-dependent. In these two forms of modified LDL, non-esterified cholesterol was susceptible to cholesterol oxidase, indicating exposure of non-esterified cholesterol on particle surfaces and suggesting a role for non-esterified cholesterol in mediating CRP binding. Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. The binding was Ca(2+)-dependent and could be competed out with phosphocholine. Taken together, these findings suggest that CRP can bind to modified lipoproteins, notably to the non-esterified cholesterol on their surface. These interactions may be related to the suggested role of CRP in the local inflammation present in atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102655      PMCID: PMC1222894          DOI: 10.1042/BJ20020492

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

Review 1.  Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL.

Authors:  T Hevonoja; M O Pentikäinen; M T Hyvönen; P T Kovanen; M Ala-Korpela
Journal:  Biochim Biophys Acta       Date:  2000-11-15

2.  Monoclonal antibody detection of plasma membrane cholesterol microdomains responsive to cholesterol trafficking.

Authors:  H S Kruth; I Ifrim; J Chang; L Addadi; D Perl-Treves; W Y Zhang
Journal:  J Lipid Res       Date:  2001-09       Impact factor: 5.922

3.  Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans.

Authors:  J K Hakala; K Oörni; M O Pentikäinen; E Hurt-Camejo; P T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

4.  Interactions of C-reactive protein with the first component of human complement.

Authors:  D R Claus; J Siegel; K Petras; A P Osmand; H Gewurz
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

5.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

6.  Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide.

Authors:  J E Volanakis; M H Kaplan
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

7.  Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin.

Authors:  M O Pentikäinen; K Oörni; P T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

Review 8.  Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima.

Authors:  M O Pentikäinen; K Oörni; M Ala-Korpela; P T Kovanen
Journal:  J Intern Med       Date:  2000-03       Impact factor: 8.989

9.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

10.  C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.

Authors:  D Gershov; S Kim; N Brot; K B Elkon
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

View more
  16 in total

1.  Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; David J Hammond; Antonio E Rusiñol; Lawrence A Potempa; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2009-06-21       Impact factor: 3.786

Review 2.  Physical activity and high-sensitivity C-reactive protein.

Authors:  Eric P Plaisance; Peter W Grandjean
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

3.  Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis.

Authors:  Sanjay K Singh; Avinash Thirumalai; David J Hammond; Michael K Pangburn; Vinod K Mishra; David A Johnson; Antonio E Rusiñol; Alok Agrawal
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

4.  Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin.

Authors:  Raul D Santos; Ana P M Chacra; Aleksandra Morikawa; Carmen C Vinagre; Raul C Maranhão
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

Review 5.  CRP after 2004.

Authors:  Alok Agrawal
Journal:  Mol Immunol       Date:  2004-12-07       Impact factor: 4.407

6.  Atherosclerosis-related functions of C-reactive protein.

Authors:  Alok Agrawal; David J Hammond; Sanjay K Singh
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-12-01

Review 7.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

8.  Induction of glycosylation in human C-reactive protein under different pathological conditions.

Authors:  Tanusree Das; Asish K Sen; Tore Kempf; Sumit R Pramanik; Chhabinath Mandal; Chitra Mandal
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

9.  Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2008-04-27       Impact factor: 3.786

Review 10.  Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP.

Authors:  Sean P Mazer; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.